PHD student, Mahmood Faraz at the Department of Radiation Sciences, Umeå University has explained that understanding the role that genes play in either promoting or holding back tumour growth, will assist in understanding the best approach to a planned course of cancer treatment.
A dissertation, authored by Farez, focussed on two genes: LRIG1 and LRIG2. Their names are derived from leucine-rich repeats and immunoglobulin-like protein domains. The role that these proteins play in causing cancer have been known for some time. However, the molecular mechanisms of these two genes has been ambiguous. It’s been the objective of a number of research teams, across the world, to explain the mechanisms of the LRIG1 and LRIG2 genes.
Håkan Hedman’s research group, of Umeå chose to experiment with mice so that they would be able to understand more about the molecular mechanisms of the two genes. Experimenting revealed two outcomes. First, that the LRIG1 gene suppresses tumour growth by countering tumour growth in the brain of the mice. Second, LRIG2 seems to act in an exact opposite way, by promoting the rise of a malignant tumour.
A thesis by Farez highlights that the tumour restricting effect of the LRIG1 gene is largely correlated with other proteins, known as receptor tyrosine kinases (RKTs). RKTs are important in understanding cancer and may contribute to many types, if they are not inhibited. LRIG1 restricts the movement of brain tumour cells through the specific RTK, known as MET (mesenchymal-epithelial transition). LRIG2, the other researched gene, enhances tumour growth by modulating downstream signalling of an RTK, known as PDGFR.
Farez also carried out another cancer study. In this second project, he was able to clearly show which proteins interact with LRIG1 to alter its purpose. Out of a near twenty proteins were looked into, he found that only four support LRIG1, while eight restrict it. This cancer research was warmly welcomed, as previously, only one protein has been known about.
In his final observations, Farez describes his findings as exciting. The research into the molecular mechanisms of the two genes is a tremendous breakthrough in this specific and heavily researched area. However, these findings are premature and more research will be necessary to expose the mechanisms, further. The work of Farez enables us to understand more about how close we are to curing cancer. As the research of Farez has shown a clear breakthrough, this supports the need for further investigation into both of these genes and how they’re related to cancer development.
Verita Life are a private hospital offering alternative cancer treatments in Bangkok, Germany and Mexico. Verita Life are interested in the research of Farez at the Umeå University, Sweden. The findings show that two genes are responsible for both suppressing and promoting the growth of malignant Brain Cancer. Further, the research is a breakthrough in revealing the molecular mechanisms of both genes. Specifically, the role that proteins we each have play in both of the genes. If you would like to speak with our specialists about the ways in which we can help you, please contact us here.
Source: Umea University